title: Quantifying mutated and unmutated BCR-ABL transcripts confirms suitability of direct sequencing sensitivity in mutation analysis of patients with chronic myeloid leukemia with secondary resistance to tyrosine kinase inhibitors, regardless of ratio values.
authors.forename: Iñigo
authors.initials: I
authors.lastname: Santamaría
authors.forename: Angel R
authors.initials: AR
authors.lastname: Payer
authors.forename: Ana S
authors.initials: AS
authors.lastname: Pitiot
authors.forename: Marta G
authors.initials: MG
authors.lastname: Alvarado
authors.forename: Milagros
authors.initials: M
authors.lastname: Balbín
mesh_terms: D004252:DNA Mutational Analysis / Q000379:methods*; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D016044:Fusion Proteins, bcr-abl / Q000235:genetics*; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics; D009154:Mutation; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*
chemical_list: D047428:Protein Kinase Inhibitors; D016044:Fusion Proteins, bcr-abl